Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

Eli Lilly’s first quarter was a bit better than Wall Street had anticipated, but it wasn’t enough for traders on Thursday ...

LLY has delivered impressive returns of 15% year-to-date, outperforming the S&P 500’s 5% decline during the same period. This ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly's first-quarter results were driven by exceptional sales of its diabetes treatment, Mounjaro, and weight loss drug, Zepbound. Mounjaro achieved $3.84 billion in revenue, a remarkable 113% ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

Summit Therapeutics (SMMT) stock plunges 35% a day after the FDA approval of partner Akeso's (AKESF) cancer drug, ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

(Bloomberg) — Morgan Stanley has hired senior dealmaker David Kostel as the vice chairman of its health-care investment banking group, people familiar with the matter said. Kostel, who had ...